ReviewWorld journal of gastroenterology2016
Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 53 citations in OpenAlex.
- Ex-vivo 7T MRI of human explanted cirrhotic liver with HCC: quantitative and qualitative evaluation with radiological-pathological correlation.La Radiologia medica · 2025Article
- Hepatic lipid droplet-associated proteome changes distinguish dietary-induced fatty liver from glucose tolerance in male mice.American journal of physiology. Endocrinology and metabolism · 2024Article
- Inflammasome-Mediated Cytokines: A Key Connection between Obesity-Associated NASH and Liver Cancer Progression.Biomedicines · 2022Review
- Non-proteolytic ubiquitylation in cellular signaling and human disease.Communications biology · 2022Review
- Bariatric surgery, obesity and liver transplantation.Translational gastroenterology and hepatology · 2022Review
- Metronidazole enhances steatosis-related early-stage hepatocarcinogenesis in high fat diet-fed rats through DNA double-strand breaks and modulation of autophagy.Environmental science and pollution research international · 2022Article
- Nod2 protects mice from inflammation and obesity-dependent liver cancer.Scientific reports · 2020Article
- Article
- Downregulated microRNA-129-5p by Long Non-coding RNA NEAT1 Upregulates PEG3 Expression to Aggravate Non-alcoholic Steatohepatitis.Frontiers in genetics · 2020Article
- Predict New Therapeutic Drugs for Hepatocellular Carcinoma Based on Gene Mutation and Expression.Frontiers in bioengineering and biotechnology · 2020Article
- Changing trends in the disease burden of primary liver cancer caused by specific etiologies in China.Cancer medicine · 2019Article
- Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets.World journal of gastroenterology · 2019Review
- A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma.Hepatology (Baltimore, Md.) · 2019Article
- Function, Detection and Alteration of Acylcarnitine Metabolism in Hepatocellular Carcinoma.Metabolites · 2019Review
- Non-proteolytic ubiquitin modification of PPARγ by Smurf1 protects the liver from steatosis.PLoS biology · 2018Article
- Prognostic importance of bile duct invasion in surgical resection with curative intent for hepatocellular carcinoma using PSM analysis.Oncology letters · 2018Article
- A Survey of Molecular Heterogeneity in Hepatocellular Carcinoma.Hepatology communications · 2018Article
- CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128.Oncotarget · 2018Article
- Non-alcoholic Fatty Liver Disease in Morbidly Obese Individuals Undergoing Bariatric Surgery: Prevalence and Effect of the Pre-Bariatric Very Low Calorie Diet.Obesity surgery · 2018Article
- Risk of Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis.Gastroenterology & hepatology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is now the fifth cancer of greatest frequency and the second leading cause of cancer related deaths worldwide. Chief amongst the risks of HCC are hepatitis B and C infection, aflatoxin B1 ingestion, alcoholism and obesity. The latter can promote non-alcoholic fatty liver disease (NAFLD), that can lead to the inflammatory form non-alcoholic steatohepatitis (NASH), and can in turn promote HCC. The mechanisms by which NASH promotes HCC are only beginning to be characterized. Here in this review, we give a summary of the recent findings that describe and associate NAFLD and NASH with the subsequent HCC progression. We will focus our discussion on clinical and genomic associations that describe new risks for NAFLD and NASH promoted HCC. In addition, we will consider novel murine models that clarify some of the mechanisms that drive NASH HCC formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.